![Sjoerd Wadman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sjoerd Wadman
Technik-/Wissenschafts-/F&E-Leiter bei LanthioPep BV
Aktive Positionen von Sjoerd Wadman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LanthioPep BV
![]() LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Sjoerd Wadman
Ehemalige bekannte Positionen von Sjoerd Wadman
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Novacta Biosystems Ltd.
![]() Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01.12.2011 | 01.12.2011 |
Morphochem AG
![]() Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Corporate Officer/Principal | 01.01.2004 | 01.01.2004 |
GSK PLC | Corporate Officer/Principal | 01.12.2000 | 01.12.2000 |
Lanthio Pharma BV
![]() Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von Sjoerd Wadman
The University of Southampton | Doctorate Degree |
The University of Manchester | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 4 |
Niederlande | 3 |
Deutschland | 2 |
Operativ
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
GSK PLC | Health Technology |
Private Unternehmen | 4 |
---|---|
LanthioPep BV
![]() LanthioPep BV Medical SpecialtiesHealth Technology LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands. | Health Technology |
Lanthio Pharma BV
![]() Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
Novacta Biosystems Ltd.
![]() Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Health Technology |
Morphochem AG
![]() Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany. | Commercial Services |
- Börse
- Insiders
- Sjoerd Wadman
- Erfahrung